UroGen Reports the First Patient Dosing with UGN-103 in P-III (UTOPIA) Study to Treat Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Shots:
- UroGen Pharma has dosed the first patient in its P-III study of UGN-103 to treat low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)
- The P-III (UTOPIA) trial will assess UGN-103 (75mg, intravesical instillation, QW for 6wks.) for treating patients (n=87) with LG-IR-NMIBC, with efficacy assessed by the CRR at 3mos. Those with no detectable disease will enter a 3mos. follow-up period, continuing until recurrence, progression, death or last patient completing 12mos. follow-up
- UGN-103, developed using UroGen’s RTGel technology, is mitomycin formulation for treating LG-IR-NMIBC that offers potential advantages, incl. a streamlined manufacturing process & simplified reconstitution
Ref: UroGen Pharma | Image: UroGen Pharma
Related News:- UroGen Pharma Reports Real-World Analysis of Jelmyto for Upper Tract Urothelial Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
